Evidence map›Paper›PMID 42321544›Full record

ArticleCommunications biology2026

Ovo, an open-source ecosystem for de novo protein design.

David Prihoda, Marco Ancona, Tereza Calounova, Adam Kral, Lukas Polak, Hugo Hrban, Nicholas J Dickens, Danny A Bitton

Abstract read
In one paragraph

Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. ProteinDJ: A high-performance and modular protein design pipeline.Protein science : a publication of the Protein Society · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

David Prihoda *Applied Research and Innovation, MSD Czech Republic s.r.o., Prague, Czech Republic.
Marco Ancona *Applied Research and Innovation, MSD Czech Republic s.r.o., Prague, Czech Republic.
Tereza Calounova *Applied Research and Innovation, MSD Czech Republic s.r.o., Prague, Czech Republic.
Adam KralApplied Research and Innovation, MSD Czech Republic s.r.o., Prague, Czech Republic.
Lukas PolakApplied Research and Innovation, MSD Czech Republic s.r.o., Prague, Czech Republic.ORCID http://orcid.org/0009-0001-6474-2949
Hugo HrbanApplied Research and Innovation, MSD Czech Republic s.r.o., Prague, Czech Republic.
Nicholas J DickensAmazon Web Services LLC, Seattle, WA, USA.
Danny A BittonApplied Research and Innovation, MSD Czech Republic s.r.o., Prague, Czech Republic. danny.bitton@msd.com.ORCID http://orcid.org/0000-0003-3282-1017

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The protein design field is rapidly advancing, with frequent emergence of new models and pipelines for designing de novo proteins with tailored properties and functions not found in nature. However, the current tool landscape is fragmented, tools are hard to install and deploy, and require significant computational expertise to integrate into end-to-end, scalable pipelines. A particular challenge is managing many sequences, structures, and metrics for downstream testing and retrospective analysis of input parameters. To address this need, we introduce Ovo, an open-source de novo protein design ecosystem that consolidates models, workflows, data management, and interactive visualization into a scalable, infrastructure-agnostic platform. Ovo features Nextflow-based workflow orchestration, a storage layer, and both command-line and graphical interfaces that democratize scaffold design, binder design and diversification, and validation workflows. Ovo's novel ProteinQC module computes comprehensive sequence and structure descriptors, contextualizing designs against reference sets. Ovo plugins let the community add new workflows and user interfaces to accelerate adoption of emerging methods and facilitate community-driven benchmarking. Ovo lowers engineering barriers and demystifies the design process, allowing experts and non-technical users to design proteins at scale. With community-driven development, Ovo can accelerate de novo protein design and advance discovery in therapeutics and biotechnology.

Indexed as

Computational BiologyProtein EngineeringProteinsSoftwareProteins

Identifiers

PMID42321544
PMCPMC13658209

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.